Physician profile
Harold Mark Lickey
NPI 1720181738
$5,891.51
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $1,386 · 2021: $2,525 · 2022: $308 · 2023: $86.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $840.43 | 2019-2022 | |
| Novo Nordisk INC | $606.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $510.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $420.04 | 2019-2022 | |
| Pfizer INC. | $392.81 | 2019-2021 | |
| Lilly USA, LLC | $329.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $285.69 | 2019-2022 | |
| Allergan, INC. | $272.93 | 2019-2020 | |
| Astellas Pharma US INC | $243.06 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $207.33 | 2019-2021 | |
| Abbvie INC. | $202.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $169.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.10 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $157.70 | 2021 | |
| Esperion Therapeutics, INC. | $127.35 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Lickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.